A Registry Study of Biomarkers in Progression of Acute Heart Failure(BIOMS-POAHF)
1 other identifier
observational
850
1 country
1
Brief Summary
The registry study aims to discover the prognostic value of bio-markers in acute heart failure
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2015
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2015
CompletedFirst Submitted
Initial submission to the registry
September 26, 2019
CompletedFirst Posted
Study publicly available on registry
September 30, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2025
CompletedSeptember 30, 2019
September 1, 2019
9.7 years
September 26, 2019
September 26, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of death ( all cause) or readmission for heart failure
Number of Death or heart failure related hospitalization within a median follow-up of 8.8 months of discharge
a median follow-up of 8.8 months
Secondary Outcomes (1)
Number of death ( all cause) or readmission for heart failure and cardiovascular mortality
a median follow-up of 8.8 months
Eligibility Criteria
Patients with heart failure accorrding to Inclusion and exclusion criteria
You may qualify if:
- \. Patients aged greater than or equal to 18 years with acute exacerbation of chronic heart failure or new heart failure
- \. With typical symptoms of acute heart failure as follows: Dyspnea, ankle swelling and fatigue (Limited activity endurance), increased jugular pressure, rales and peripheral edema ;
- \. Plasma concentrations of BNP: BNP\>100pg/ML
- \. Echocardiography: Related structural heart disease (left ventricular hypertrophy and/or left atrial enlargement) and/or diastolic dysfunction
You may not qualify if:
- \. Previous history of cancer or renal replacement therapy
- Surgery was performed within a month
- Accompanied by cardiogenic shock, sepsis, pneumonia
- Eligible patients without informed consent form
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Beijing Anzhen Hospital
Beijing, 100029, China
Related Publications (1)
Ma K, Yang J, Shao Y, Li P, Guo H, Wu J, Zhu Y, Zhang H, Zhang X, Du J, Li Y. Therapeutic and Prognostic Significance of Arachidonic Acid in Heart Failure. Circ Res. 2022 Apr;130(7):1056-1071. doi: 10.1161/CIRCRESAHA.121.320548. Epub 2022 Mar 8.
PMID: 35255710DERIVED
Biospecimen
Blood Samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Jie Du, PHD
Beijing Anzhen Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 26, 2019
First Posted
September 30, 2019
Study Start
December 1, 2015
Primary Completion
August 1, 2025
Study Completion
October 1, 2025
Last Updated
September 30, 2019
Record last verified: 2019-09